Abstracts Archive - Page 903 of 1683 - ATC Abstracts

2018 American Transplant Congress
Impact of Glomerular Filtration Rate Normalization to Body Surface Area on Donor Selection and Outcome in over 4000 Living Kidney Donors
S. Riad,¹ D. Keys,¹ D. Vock,¹ S. Jackson,¹ D. Berglund,¹ V. Vakil,¹ A. Matas,¹ H. Ibrahim.³
¹U of MN, Minneapolis; ²Houston Methodist, Houston.
Introduction: A donor GFR of ≥ 80 mL/min is a selection criterion. KDIGO recommends that GFR indexed to BSA should be used. Herein, we tested…
2018 American Transplant Congress
Microbiology and Outcomes of Febrile Neutropenia Episodes after Kidney Transplant
G. Dube, S. Husain, H. Morris, D. Cohen, S. Mohan.
Medicine, Columbia University Medical Center, New York, NY.
Febrile neutropenia (FN) is a common complication in cancer patients receiving chemotherapy. Neutropenia is common after kidney transplant (KT), but little is known about the…
2018 American Transplant Congress
The Impact of Induction Agent on Development of Febrile Neutropenia Following Kidney Transplant
G. Dube, S. Husain, D. Cohen, S. Mohan.
Medicine, Columbia University Medical Center, New York, NY.
Neutropenia is common after kidney transplant (KT), usually due to medication side effects (induction agents maintenance medications, antibiotics), and is associated with worse patient and…
2018 American Transplant Congress
Having Your Cake and Eating It Too: An Aggressive Protocol for DSA Treatment Does Not Doom Patients to High Infectious Risk
A. Murthy, A. Karaballa, G. Vranic, B. Javaid, J. Moore, S. Yi, J. Verbesey, P. Abrams, S. Ghasemian, M. Cooper, A. Gilbert.
Medstar Georgetown Transplant Institute, Medstar Georgetown University Hospital, Washington, DC.
Introduction: Antibody mediated rejection (AMR) is one of the most difficult complications to treat in kidney transplantation. We previously reported on our experience with an…
2018 American Transplant Congress
Urinary Tract Infections May Be Associated with De Novo Donor-Specific Anti-Human Leucocyte Antigen Antibodies: Single-Center Study
M. Everly,¹ A. Babu,¹ K. Briley,² P. Bolin,² S. Kendrick,³ H. Jones,³ K. McLawhorn,³ A. Maldonado,⁴ C. Haisch,² D. Leeser,² L. Rebellato.²
¹Terasaki Research Institute, Los Angeles; ²East Carolina University, Greenville, NC; ³Eastern Nephrology Associates, Greenville, NC; ⁴Vidant Medical Center, Greenville, NC.
Introduction: We have recently shown that immunosuppression reduction with BK virus is associated with the development of de novo donor anti-human leukocyte antigen-specific antibodies (dnDSA).…
2018 American Transplant Congress
The Role of Pre-Emptive Antibiotic Therapy in Kidney Recipients of Donors with Urine-Only Positive Cultures
P. Cabrera,¹ A. Centeno,¹ J. Revollo,¹ J. Camargo.²
¹Department of Pharmacy, Jackson Memorial Hospital, Miami, FL; ²Department of Medicine, University of Miami Miller School of Medicine, Miami, FL.
Background: Donor derived infections (DDIs) can lead to significant morbidity and mortality in solid organ transplant patients. In recent years, the disparity between the need…
2018 American Transplant Congress
Impact of Direct Antiviral Therapy for Hepatitis C on Acute Rejection and DSA Formation in Kidney Transplant Recipients
Z. Zaky, S. Armanyous, L. Herlitz, E. Poggio, J. Augustine.
Cleveland Clinic, Cleveland, OH.
Background: Hepatitis C virus infection (HCV) has historically portended a poor outcome after kidney transplantation. With recent advent of direct antiviral agents (DAA), there has…
2018 American Transplant Congress
Safety and Efficacy of Sofosbuvir-Based Direct-Acting Antiviral Agents in Kidney Transplant Recipients with HCV: A Systematic Review and Meta-Analysis
X. Wang,¹ P. Tan,¹ T. Xiang,² Y. Qiu,¹ T. Song,¹ T. Lin.¹
¹Department of Urology/Institute of Urology/Organ Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China; ²West China School of Clinical Medicine, Sichuan University, Chengdu, Sichuan Province, China.
Background: Outcome data on sofosbuvir (SOF)-based therapy in patients with kidney transplantation (KTx) with hepatitis C virus infection are limited with individual studies having a…
2018 American Transplant Congress
Elbasvir-Grazoprevir (Zepatier) is Effective and Safe for the Treatment of Chronic Hepatitis C (HCV) Genotype 1 Virus in the Post Kidney Transplant Patient
P. Brown, D. Venkat.
Henry Ford Hospital, Detroit.
Objective: Limited real world data exists regarding the use of direct acting antivirals (DAA) for HCV viremia in renal transplant patients, particularly those with marked…
2018 American Transplant Congress
One-Year Outcomes in Patients with Advanced Liver Fibrosis or Compensated Cirrhosis from Chronic Hepatitis C Receiving Kidney Transplant Alone
P. Brown, F. Kumssa, D. Venkat.
Henry Ford Hospital, Detroit.
Background: Hepatitis C (HCV) was difficult to treat post-kidney transplant prior to the direct acting antiviral (DAA) era. As such patients with advanced fibrosis and…